Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    July 2019
  1. CAUMANNS JJ, van Wijngaarden A, Kol A, Meersma GJ, et al
    Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer Lett. 2019 Jul 15. pii: S0304-3835(19)30400.
    PubMed     Text format     Abstract available


  2. PARAYATH NN, Gandham SK, Leslie F, Amiji MM, et al
    Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
    Cancer Lett. 2019;461:1-9.
    PubMed     Text format     Abstract available


    June 2019
  3. CHEN J, Deng Y, Ao L, Song Y, et al
    The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF-beta/Smad pathway in cervical cancer.
    Cancer Lett. 2019 Jun 24. pii: S0304-3835(19)30376.
    PubMed     Text format     Abstract available


  4. ZHANG M, Jabbari N, Satpathy M, Matyunina LV, et al
    Sequence diverse miRNAs converge to induce mesenchymal-to-epithelial transition in ovarian cancer cells through direct and indirect regulatory controls.
    Cancer Lett. 2019 Jun 1. pii: S0304-3835(19)30340.
    PubMed     Text format     Abstract available


    May 2019
  5. KREUZINGER C, von der Decken I, Wolf A, Gamperl M, et al
    Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Cancer Lett. 2019;459:1-12.
    PubMed     Text format     Abstract available


  6. FOGG KC, Olson WR, Miller JN, Khan A, et al
    Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.
    Cancer Lett. 2019 May 23. pii: S0304-3835(19)30324.
    PubMed     Text format     Abstract available


    March 2019
  7. HAN W, Zhang Y, Niu C, Guo J, et al
    BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
    Cancer Lett. 2019;445:45-56.
    PubMed     Text format     Abstract available


  8. CHE Y, Li Y, Zheng F, Zou K, et al
    TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
    Cancer Lett. 2019;452:1-13.
    PubMed     Text format     Abstract available


    February 2019
  9. VLIET-GREGG PA, Robinson KL, Levan J, Matsumoto LR, et al
    NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells.
    Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30102.
    PubMed     Text format     Abstract available


    November 2018
  10. RADHAKRISHNAN R, Ha JH, Jayaraman M, Liu J, et al
    Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30689.
    PubMed     Text format     Abstract available


    October 2018
  11. LV Q, Xie L, Cheng Y, Shi Y, et al
    A20-mediated deubiquitination of ERalpha in the microenvironment of CD163(+) macrophages sensitizes endometrial cancer cells to estrogen.
    Cancer Lett. 2018;442:137-147.
    PubMed     Text format     Abstract available


  12. PENG Y, Kajiyama H, Yuan H, Nakamura K, et al
    PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Cancer Lett. 2018;442:181-192.
    PubMed     Text format     Abstract available


    September 2018
  13. YANG P, Su C, Luo X, Zeng H, et al
    Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway.
    Cancer Lett. 2018 Sep 10. pii: S0304-3835(18)30559.
    PubMed     Text format     Abstract available


    August 2018
  14. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett. 2018 Feb 28; 415:20-29].
    Cancer Lett. 2018 Aug 18. pii: S0304-3835(18)30502.
    PubMed     Text format    


  15. KREITZBURG KM, Fehling SC, Landen CN, Gamblin TL, et al
    FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Cancer Lett. 2018 Aug 15. pii: S0304-3835(18)30527.
    PubMed     Text format     Abstract available


  16. CHEN X, Zhou J, Li X, Wang X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.
    Cancer Lett. 2018;435:80-91.
    PubMed     Text format     Abstract available


    July 2018
  17. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Text format     Abstract available


    June 2018
  18. MALDONADO L, Brait M, Izumchenko E, Begum S, et al
    Integrated Transcriptomic and Epigenomic Analysis of Ovarian Cancer Reveals Epigenetically Silenced GULP1.
    Cancer Lett. 2018 Jun 28. pii: S0304-3835(18)30436.
    PubMed     Text format     Abstract available


  19. ZHANG Q, Li Y, Miao C, Wang Y, et al
    Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.
    Cancer Lett. 2018 Jun 4. pii: S0304-3835(18)30390.
    PubMed     Text format     Abstract available


    April 2018
  20. MENG Y, Chen CW, Yung MMH, Sun W, et al
    DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30296.
    PubMed     Text format     Abstract available


  21. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Text format     Abstract available


    March 2018
  22. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Text format     Abstract available


  23. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Text format     Abstract available


    February 2018
  24. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Text format     Abstract available


  25. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Text format     Abstract available


    January 2018
  26. GUO J, Yang Z, Yang X, Li T, et al
    miR-346 functions as a pro-survival factor under ER stress by activating mitophagy.
    Cancer Lett. 2018;413:69-81.
    PubMed     Text format     Abstract available


    December 2017
  27. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Text format     Abstract available


    November 2017
  28. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Text format     Abstract available


    October 2017
  29. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Text format     Abstract available


  30. WANG J, Man GCW, Chan TH, Kwong J, et al
    A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30623.
    PubMed     Text format     Abstract available


  31. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Text format     Abstract available


  32. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Text format     Abstract available


    September 2017
  33. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: